Compare AU

Compare NDQ vs. CURE

Compare shares and ETFs on the ASX that you can trade on Pearler.

BetaShares Nasdaq 100 ETF

ASX

Buy

Buy

Overview
Performance

Overview

When it comes to investing in the Australian stock market, Exchange-Traded Funds (ETFs) are a popular choice. Two well-known options in the Australian Securities Exchange (ASX) are the BetaShares Nasdaq 100 ETF (NDQ) and the Global X S&P Biotech ETF (CURE). In this comparison, we'll delve into these ETFs across various dimensions to help you make an informed investment decision.

Community Stats

NDQ

CURE

Popularity

Medium

Low

Pearlers invested

5,847

80

Median incremental investment

$997.50

$620.00

Median investment frequency

Monthly

Monthly

Median total investment

$2,962.06

$1,284.19

Average age group

26 - 35

> 35


Key Summary

NDQ

CURE

Strategy

BetaShares Nasdaq 100 ETF (ASX: NDQ) seeks to track the performance of the NASDAQ 100 index before account fees, expenses and taxes. The index tracks 100 of the largest non-financial companies listed on the NASDAQ market.

CURE.AX was created on 2018-11-08 by Global X. The fund's investment portfolio concentrates primarily on health care equity. The Fund aims to provide investors with a return that (before fees and expenses) tracks the performance of the S&P Biotechnology Select Industry Index.

Top 3 holdings

APPLE INC (8.87 %)

NVIDIA CORP (8.41 %)

MICROSOFT CORP (8.12 %)

Neurocrine Biosciences Inc (2.72 %)

Natera Inc (2.49 %)

Gilead Sciences Inc (2.45 %)

Top 3 industries

Information Technology (50.23 %)

Consumer Discretionary (14.75 %)

Communication Services (11.95 %)

Health Care (100.00 %)

Other (10.24 %)

Top 3 countries

United States (97.15 %)

Netherlands (0.92 %)

Brazil (0.69 %)

United States (97.17 %)

Switzerland (1.51 %)

United Kingdom of Great Britain and Northern Ireland (1.16 %)

Management fee

0.48 %

0.45 %


Key Summary

NDQ

CURE

Issuer

BetaShares

Global X

Tracking index

NASDAQ 100 Index

S&P Biotechnology Select Industry

Asset class

ETF

ETF

Management fee

0.48 %

0.45 %

Price

$51.07

$48.46

Size

$6.069 billion

$34.226 million

10Y return

N/A

N/A

Annual distribution yield (5Y)

2.88 %

4.24 %

Market

ASX

ASX

First listed date

26/05/2015

12/11/2018

Purchase fee

$6.50

$6.50


Community Stats

NDQ

CURE

Popularity

Medium

Low

Pearlers invested

5,847

80

Median incremental investment

$997.50

$620.00

Median investment frequency

Monthly

Monthly

Median total investment

$2,962.06

$1,284.19

Average age group

26 - 35

> 35


Pros and Cons

NDQ

CURE

Pros

  • Higher price growth

  • Higher exposure to US market

  • Lower management fee

  • Higher distribution yield

Cons

  • Lower exposure to US market

  • Higher management fee

  • Lower distribution yield

  • Lower price growth

NDQ

CURE

Lower exposure to US market

Higher exposure to US market

Higher management fee

Lower management fee

Higher price growth

Lower price growth

Lower distribution yield

Higher distribution yield

Home